PHASE-I STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND SLEEP PROMOTING ACTIVITY OF Neu-P11, A NOVEL PUTATIVE INSOMNIA DRUG IN HEALTHY HUMANS

被引：0

作者：

Yalkinoglu, Oe ^{[1
]}

Zisapel, N. ^{[4
]}

Nir, T. ^{[4
]}

Piechatzek, R. ^{[1
]}

Schorr-Neufing, U. ^{[1
]}

Bitterlich, N. ^{[1
]}

Oertel, R. ^{[3
]}

Allgaier, C. ^{[2
]}

Kluge, A. ^{[1
]}

Laudon, M. ^{[4
]}

机构：

[1] ABX CRO Adv Pharmaceut Serv Forsch GmbH, Dresden, Germany

[2] ACA Pharma Concept GmbH, Leipzig, Germany

[3] Tech Univ, Inst Clin Pharmacol, Fac Med, Dresden, Germany

[4] Neurim Pharmaceut Ltd, Tel Aviv, Israel

来源：

SLEEP | 2010年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

0656

引用

页码：A220 / A220

页数：1

共 35 条

[1] Neu-P11: a novel drug for the treatment of insomnia and central sensitivity syndrome symptoms - results of a Phase-Ib study
Katz, A.
Metzger, D.
Staner, L.
Pross, N.
Cornette, F.
Guichard, N.
Laudon, M.
Nir, T.
Zisapel, N.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S220 - S221
[2] Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings
Koshimichi, Hiroki
Ishibashi, Toru
Kawaguchi, Nao
Sato, Chisako
Kawasaki, Akira
Wajima, Toshihiro
CLINICAL DRUG INVESTIGATION, 2018, 38 (12) : 1189 - 1196
[3] Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings
Hiroki Koshimichi
Toru Ishibashi
Nao Kawaguchi
Chisako Sato
Akira Kawasaki
Toshihiro Wajima
Clinical Drug Investigation, 2018, 38 : 1189 - 1196
[4] Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
Yap, Desmond Y. H.
Hai, Jojo
Lee, Paul C. H.
Zhou, Xueying
Lee, Michael
Zhang, Yu
Wang, Meng
Chen, Xiaoxiang
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1769 - 1779
[5] A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects
Chen, Qian
Wu, Qingqing
Song, Rong
Wang, Yating
Zhang, Mengqi
Li, Fangqiong
Zeng, Weifang
Wang, Wei
Jia, Jingying
Yu, Chen
Liu, Yanmei
FRONTIERS IN PHARMACOLOGY, 2023, 14
[6] A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects
Ma, Junlong
Huang, Jie
Zou, Chan
Wu, Qian
Xie, Jinlian
Zhang, Xingfei
Yang, Xiaoyan
Yang, Shuang
Wu, Ziteng
Jiang, Yan
Yu, Sen
Zhang, Xuqing
Yang, Guoping
Li, Mingyuan
DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 2303 - 2313
[7] A phase I, single and continuous dose administration study on the safety, tolerability, and pharmacokinetics of neorudin, a novel recombinant anticoagulant protein, in healthy subjects
Liu, Yubin
Wang, Meixia
Dong, Xiaona
He, Jia
Zhang, Lin
Zhou, Ying
Xia, Xia
Dou, Guifang
Wu, Chu-tse
Jin, Jide
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (03):
[8] First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults
Mammen, Mammen P.
Armas, Danielle
Hughes, Frank H.
Hopkins, Andrew M.
Fisher, Cindy L.
Resch, Pamela A.
Rusalov, Denis
Sullivan, Sean M.
Smith, Larry R.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (11)
[9] Eye drops of Novel Synthetic Peptide for neovascular age related macular degeneration : Safety, tolerability and pharmacokinetics study in healthy volunteers (phase I study)
Kwak, Hyunduck
Ghim, Jong-Lyul
Ahn, Byulnim
Woo, Taegyu
Kim, Suyeon
Jang, Jin-Wook
Cho, Yunseok
Yang, Jaewook
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[10] Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects
Qian, Hongjie
Yu, Chengyin
Zhu, Huijuan
Ding, Qichen
Cai, Yuting
Jing, Jiao
Xu, Xin
Guo, Runcong
Zhang, Haiyan
Liu, Hong
Chen, Xiaoyan
Liu, Yun
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (05): : 810 - 822

← 1 2 3 4 →